212 related articles for article (PubMed ID: 24222719)
1. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis.
Spinelli FR; Metere A; Barbati C; Pierdominici M; Iannuccelli C; Lucchino B; Ciciarello F; Agati L; Valesini G; Di Franco M
Mediators Inflamm; 2013; 2013():537539. PubMed ID: 24222719
[TBL] [Abstract][Full Text] [Related]
2. Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis.
Park YJ; Kim JY; Park J; Choi JJ; Kim WU; Cho CS
Arthritis Rheumatol; 2014 Jun; 66(6):1450-60. PubMed ID: 24991663
[TBL] [Abstract][Full Text] [Related]
3. Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis.
Spinelli FR; Di Franco M; Metere A; Conti F; Iannuccelli C; Agati L; Valesini G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S67-9. PubMed ID: 25381982
[TBL] [Abstract][Full Text] [Related]
4. Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis.
Korkosz M; Gąsowski J; Surdacki A; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
Pharmacol Rep; 2013; 65(4):891-7. PubMed ID: 24145083
[TBL] [Abstract][Full Text] [Related]
5. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis.
Grisar J; Aletaha D; Steiner CW; Kapral T; Steiner S; Seidinger D; Weigel G; Schwarzinger I; Wolozcszuk W; Steiner G; Smolen JS
Circulation; 2005 Jan; 111(2):204-11. PubMed ID: 15642766
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis.
Ablin JN; Boguslavski V; Aloush V; Elkayam O; Paran D; Caspi D; George J
Life Sci; 2006 Nov; 79(25):2364-9. PubMed ID: 16962143
[TBL] [Abstract][Full Text] [Related]
7. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study.
Sandoo A; Kitas GD; Carroll D; Veldhuijzen van Zanten JJ
Arthritis Res Ther; 2012 May; 14(3):R117. PubMed ID: 22594788
[TBL] [Abstract][Full Text] [Related]
8. Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity.
Jodon de Villeroché V; Avouac J; Ponceau A; Ruiz B; Kahan A; Boileau C; Uzan G; Allanore Y
Arthritis Res Ther; 2010; 12(1):R27. PubMed ID: 20158894
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
[TBL] [Abstract][Full Text] [Related]
10. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
[TBL] [Abstract][Full Text] [Related]
11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
12. Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy.
Martini G; Biscaro F; Boscaro E; Calabrese F; Lunardi F; Facco M; Agostini C; Zulian F; Fadini GP
BMC Musculoskelet Disord; 2015 Apr; 16():103. PubMed ID: 25925313
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients.
Mazzoccoli G; Notarsanto I; de Pinto GD; Dagostino MP; De Cata A; D'Alessandro G; Tarquini R; Vendemiale G
Intern Emerg Med; 2010 Dec; 5(6):495-500. PubMed ID: 20845087
[TBL] [Abstract][Full Text] [Related]
14. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
17. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
Kobie JJ; Zheng B; Bryk P; Barnes M; Ritchlin CT; Tabechian DA; Anandarajah AP; Looney RJ; Thiele RG; Anolik JH; Coca A; Wei C; Rosenberg AF; Feng C; Treanor JJ; Lee FE; Sanz I
Arthritis Res Ther; 2011; 13(6):R209. PubMed ID: 22177419
[TBL] [Abstract][Full Text] [Related]
18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
19. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
[TBL] [Abstract][Full Text] [Related]
20. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.
McGeough CM; Berrar D; Wright G; Mathews C; Gilmore P; Cunningham RT; Bjourson AJ
Rheumatol Int; 2012 Jun; 32(6):1647-53. PubMed ID: 21373785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
